Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in many cancer cells without causing toxicity in vivo. However, to date, TRAIL-receptor agonists have only shown limited therapeutic benefit in clinical trials. This can, most likely, be attributed to the fact that...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemke, J, von Karstedt, S, Abd El Hay, M, Conti, A, Arce, F, Montinaro, A, Papenfuss, K, El-Bahrawy, M A, Walczak, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921597/
https://www.ncbi.nlm.nih.gov/pubmed/24362439
http://dx.doi.org/10.1038/cdd.2013.179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921597/
https://www.ncbi.nlm.nih.gov/pubmed/24362439
http://dx.doi.org/10.1038/cdd.2013.179

Ejemplares similares